Last reviewed · How we verify

NCT04910477

Nebulized Dexmedetomidine Versus Neostigmine/Atropine in Postdural Puncture Headache

Completed Phase 3 Last updated 8 September 2021
What this trial tests

Phase 3 trial testing Dexmedetomidine in Postdural Puncture Headache in 90 participants. Completed in 3 September 2021.

Timeline
1 June 2021
Primary endpoint
1 September 2021
3 September 2021

Quick facts

Lead sponsorAssiut University
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment90
Start date1 June 2021
Primary completion1 September 2021
Estimated completion3 September 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 18 to 40, female only, with Postdural Puncture Headache. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In our study, we will compare a new route of nebulization for effectiveness between dexmedetomidine, neostigmine/atropine and saline placebo for females complained of postdural puncture headache (PDPH) after cesarean section.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

Other recruiting trials for Postdural Puncture Headache

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04910477.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing